Your browser doesn't support javascript.
loading
Bridging communities in the field of nanomedicine.
Halamoda-Kenzaoui, Blanka; Baconnier, Simon; Bastogne, Thierry; Bazile, Didier; Boisseau, Patrick; Borchard, Gerrit; Borgos, Sven Even; Calzolai, Luigi; Cederbrant, Karin; Di Felice, Gabriella; Di Francesco, Tiziana; Dobrovolskaia, Marina A; Gaspar, Rogério; Gracia, Belén; Hackley, Vincent A; Leyens, Lada; Liptrott, Neill; Park, Margriet; Patri, Anil; Roebben, Gert; Roesslein, Matthias; Thürmer, René; Urbán, Patricia; Zuang, Valérie; Bremer-Hoffmann, Susanne.
Affiliation
  • Halamoda-Kenzaoui B; European Commission Joint Research Centre (JRC), Ispra, Italy.
  • Baconnier S; Université Grenoble Alpes, CEA LETI MlNATEC Campus, Grenoble, France.
  • Bastogne T; Université de Lorraine, CNRS, CRAN, INRIA BIGS, Nancy, France.
  • Bazile D; CMC External Innovation, Sanofi, Gentilly, France.
  • Boisseau P; Université Grenoble Alpes, CEA LETI MlNATEC Campus, Grenoble, France.
  • Borchard G; Université de Genève, Ecole de Pharmacie Genève-Lausanne, Genève, Switzerland.
  • Borgos SE; SINTEF Industry, Trondheim, Norway.
  • Calzolai L; European Commission Joint Research Centre (JRC), Ispra, Italy.
  • Cederbrant K; Swedish Toxicology Sciences Research Center (Swetox), Södertälje, Sweden.
  • Di Felice G; National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma, Italy.
  • Di Francesco T; Université de Genève, Ecole de Pharmacie Genève-Lausanne, Genève, Switzerland.
  • Dobrovolskaia MA; Nanotechnology Characterization Laboratory (NCL), Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Sponsored By the National Cancer Institute, Frederick, USA.
  • Gaspar R; Faculty of Pharmacy and Institute for Bioengineering and Biosciences of the University of Lisbon, Lisboa Portugal.
  • Gracia B; Department of Medicines for Human Use, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.
  • Hackley VA; National Institute of Standards and Technology (NIST), Materials Measurement Science Division, Gaithersburg, USA.
  • Leyens L; Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
  • Liptrott N; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom.
  • Park M; RIVM- National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Patri A; U.S. Food & Drug Administration (FDA), Nanotechnology Core Facility, Jefferson, USA.
  • Roebben G; European Commission Joint Research Centre (JRC), Geel, Belgium.
  • Roesslein M; Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.
  • Thürmer R; BfArM - Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Urbán P; European Commission Joint Research Centre (JRC), Ispra, Italy.
  • Zuang V; European Commission Joint Research Centre (JRC), Ispra, Italy.
  • Bremer-Hoffmann S; European Commission Joint Research Centre (JRC), Ispra, Italy. Electronic address: susanne.bremer-hoffmann@ec.europa.eu.
Regul Toxicol Pharmacol ; 106: 187-196, 2019 Aug.
Article in En | MEDLINE | ID: mdl-31051191
ABSTRACT
An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled "Bridging communities in the field of Nanomedicine" in Ispra/Italy on the 27th -28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarised in the format of a survey.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Nanomedicine Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Nanomedicine Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Year: 2019 Type: Article